Details for Patent: 8,067,436

Title:	c-Met modulators and methods of use
Abstract:	The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
Inventor(s):	Bannen; Lynne Canne (Pacifica, CA), Chan; Diva Sze-Ming (San Francisco, CA), Chen; Jeff (San Francisco, CA), Dalrymple; Lisa Esther (San Leandro, CA), Forsyth; Timothy Patrick (Hayward, CA), Huynh; Tai Phat (Oakland, CA), Jammalamadaka; Vasu (Pleasanton, CA), Khoury; Richard George (Redwood City, CA), Leahy; James William (San Leandro, CA), Mac; Morrisson B. (San Francisco, CA), Mann; Grace (Brisbane, CA), Mann; Larry W. (Richland, MI), Nuss; John M. (Danville, CA), Parks; Jason Jevious (Sacramento, CA), Takeuchi; Craig Stacy (Burlingame, CA), Wang; Yong (Forster City, CA), Xu; Wie (Danville, CA)
Assignee:	Exelixis, Inc. (South San Francisco, CA)
Filing Date:	May 24, 2007
Application Number:	11/753,514
Claims:	1. A method of treating a disease or disorder, comprising administering to a mammal in need of the treatment a therapeutically effective amount of a compound having the following structure: ##STR00548## or a pharmaceutically acceptable salt thereof, or a composition containing a) a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof; and optionally b) an excipient, wherein the disease or disorder is, ovarian cancer, prostate cancer, or lung cancer or a pharmaceutically acceptable salt thereof. 2. The method according to claim 1, wherein the disease or disorder is lung cancer. 3. The method according to claim 1, wherein the disease or disorder is ovarian cancer. 4. The method according to claim 1, wherein the disease or disorder is prostate cancer.